Immutep (XTER:YP1A) EBIT per Share : €0.00 (TTM As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Immutep EBIT per Share?

Immutep's EBIT per Share for the three months ended in Dec. 2023 was €0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00.

During the past 3 years, the average EBIT per Share Growth Rate was -8.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was 1.70% per year. During the past 10 years, the average EBIT per Share Growth Rate was 14.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Immutep's EBIT per Share or its related term are showing as below:

XTER:YP1A' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -61.2 Med: 7.7 Max: 41.2
Current: -8.5

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Immutep was 41.20% per year. The lowest was -61.20% per year. And the median was 7.70% per year.

XTER:YP1A's 3-Year EBIT Growth Rate is ranked worse than
64.15% of 1311 companies
in the Biotechnology industry
Industry Median: 3.6 vs XTER:YP1A: -8.50

Immutep's EBIT for the three months ended in Dec. 2023 was €0.00 Mil.

Immutep EBIT per Share Historical Data

The historical data trend for Immutep's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep EBIT per Share Chart

Immutep Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EBIT per Share

Get a 7-Day Free Trial

-0.54

-0.40

-0.91

-1.03

-1.19

Immutep Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-	-	-	-	-

Immutep EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Immutep's EBIT per Share for the fiscal year that ended in Jun. 2023 is calculated as

	EBIT per Share		(A: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-24.702	/	20.7974
=	-1.19

Immutep's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	0	/	23.9933
=	0.00

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00

Immutep (XTER:YP1A) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Immutep EBIT per Share Related Terms

Thank you for viewing the detailed overview of Immutep's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Immutep (XTER:YP1A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (XTER:YP1A) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

PRRUF:USA IMMP:USA YP1B:Germany IMM:Australia

Address

264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000

Website

https://www.immutep.com

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Immutep (XTER:YP1A) Headlines

No Headlines